New York 2023-2024 Regular Session

New York Assembly Bill A06311

Introduced
4/3/23  
Refer
4/3/23  

Caption

Relates to purchasing restrictions and investment of certain public funds in persons that elect not to dispense mifepristone; requires the commissioner to develop and publish, using credible information available to the public, a list of persons determined by the commissioner, that have elected not to dispense mifepristone.

Companion Bills

No companion bills found.

Previously Filed As

NY S01091

Relates to purchasing restrictions and investment of certain public funds in persons that contract to build a border wall; requires the commissioner to develop and publish, using credible information available to the public, a list of persons determined by the commissioner, that have contracted to build a border wall.

NY S00328

Relates to purchasing restrictions and investment of certain public funds in persons that contract to build a border wall; requires the commissioner to develop and publish, using credible information available to the public, a list of persons determined by the commissioner, that have contracted to build a border wall.

NY A10083

Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.

NY A10428

Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.

NY S08656

Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.

NY A09217

Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.

NY S08544

Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.

NY HB05714

An Act Requiring The Provision Of Written Information By Pharmacists Concerning The Effects Of Mifepristone When Dispensing To A Patient.

NY A10623

Designates that the commissioners of public service shall be elected in a manner to be prescribed by law.

NY CACR30

relating to the public utilities commissioners.Providing that the public utilities commissioners are elected.

Similar Bills

CA AB54

An act to add Chapter 25 (commencing with Section 27050) to Division 20 of the Health and Safety Code, relating to reproductive health.

NJ SR22

Urges United States Supreme Court to protect freedom of reproductive choice with respect to use of and access to mifepristone.

HI SR44

Supporting The Department Of Health's Efforts To Coordinate The Stockpiling Of A Three-year Supply Of Mifepristone.

NM HB236

Notice For Medication Abortions

HI SB1246

Relating To Health Care.

HI SCR45

Supporting The Department Of Health's Efforts To Coordinate The Stockpiling Of A Three-year Supply Of Mifepristone.

US HR1285

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

US SR732

A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.